Financial Data and Key Metrics Changes - The company achieved strong year-over-year revenue growth of 8%, with total revenues for Q3 2025 reaching $12.5 million [5][14] - Operating expenses were reduced by 12% to $5.4 million compared to $6.2 million in Q3 2024, contributing to improved financial performance [5][18] - Adjusted EBITDA improved by $1.3 million, resulting in a loss of $131,000 for Q3 2025, compared to a loss of $1.4 million in the prior year [5][18] - Cash and cash equivalents totaled $5.6 million at the end of Q3 2025, a decrease of $1.2 million from the previous quarter [18] Business Line Data and Key Metrics Changes - The glaucoma product line saw a revenue increase of 13% year-over-year, totaling $3.5 million [15] - Retina product revenue increased by 4% to $6.7 million, driven by higher Pascal system sales, despite a decrease in surgical retina probe sales [15] - CycloG6 system sales increased to 30 units from 26 in the prior year, indicating strong demand and utilization [9] Market Data and Key Metrics Changes - International glaucoma performance was strong, particularly in Europe, the Middle East, and Africa, with positive contributions across geography [10] - The Asia market faced challenges due to macro factors, including a tariff dispute with China and currency fluctuations affecting Japan [10][12] - Latin America and Canada showed improved momentum following the appointment of new distributors [11] Company Strategy and Development Direction - The company is focused on streamlining operations and advancing towards profitability, with a goal of achieving cash flow positive operations in 2026 [4][20] - Cost reduction programs implemented in late 2024 have significantly lowered operating expenses and improved the financial position [5][18] - The company is negotiating with contract manufacturers to reduce the cost of goods sold and enhance gross margins [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving positive cash flows in Q4 2025 and positive adjusted EBITDA for the full year [4][19] - The company remains committed to cost discipline and improving financial performance, with expectations of sustained cash flow positivity [20] - Management acknowledged the challenges in the Asia market but noted solid underlying demand for products [12] Other Important Information - A one-time inventory write-down impacted gross profit, but excluding this charge, gross margin would have improved to 38.7% [16][18] - The company is relocating certain administrative functions to generate savings, expected to be approximately $165,000 quarterly starting Q1 2026 [6] Q&A Session Summary - No specific questions or answers were provided in the content regarding the Q&A session.

Financing Transactions - Boson Quantum completed a Series A+ financing round, raising hundreds of millions of RMB, with investments from Qif Capital and GF Xinde, focusing on the development and industrialization of domestic optical quantum computers [1] - Tongchuang Purun, a leading manufacturer of high-purity metal materials, secured 1 billion RMB in Pre-IPO financing, with investors including SAIC Group's Shangqi Capital, addressing critical material needs in the semiconductor and display panel industries [1] - Aishi Technology, an AIGC video platform, raised 100 million RMB in Series B+ financing, backed by Fosun Ruijing Capital and Shunxi Fund, focusing on AI video generation technology [2] - Zero Gravity Aircraft Industry, specializing in eVTOL aircraft, completed a Series A+ financing round of 300 million RMB, with investments from Fangguang Capital and Sichuan Industrial Revitalization Fund, aligning with the national "low-altitude economy" strategy [2] - Jiushi Intelligent, a global L4 autonomous driving company, raised hundreds of millions of USD in Series C financing led by Ant Group, focusing on B2B urban freight solutions [3] - Tupu Medical, a leader in high-end ophthalmic medical equipment, completed a strategic financing round with investors including Beijing Guoguan, aiming to break the monopoly of imported brands in the high-end ophthalmic equipment market [3] - Wolant Aviation, engaged in eVTOL development, completed hundreds of millions of RMB in Series B financing, attracting top-tier investment institutions [4] - Revolut, a leading fintech platform, secured a strategic financing round of up to 3 billion USD (approximately 19.5 billion RMB), enhancing its position as Europe's most valuable fintech unicorn [4] - Lila Sciences, an innovative tech company, completed 115 million USD in Series A financing, with investments from General Catalyst and Nvidia, highlighting the potential of AI for science [5] - Trogenix, a UK-based biotech company focused on innovative cancer gene therapies, raised 95 million USD in Series A financing, receiving investments from Eli Lilly and several specialized medical venture funds [5]

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 暂定议程 报名：首届全球心血管大会 | 奖项报名倒计时 报名：首届全球骨科大会 | 奖项报名倒计时 近日， 图湃（北京）医疗科技有限公司 完成了 总规模达到 5亿元人民币 的E轮融资 ，这是中国眼科 医疗设备领域史上已公开的一级市场投融资事件中 单笔金额最高的融资 。 在完成本轮融资后，公司 将向 科创板眼科医疗设备"第一股" 发起冲击。 本轮融资由社保基金中关村自主创新专项基金（由君联资本担任管理人）、北京机器人产业投资基金、 启明创投共同投资。这是公司继2024年6月完成D轮融资后，一年内再次受到顶级投资机构的青睐。所 融资金将持续用于公司 丰富产品矩阵及加强全球范围的市场布局 等。 自成立之初，图湃医疗就立足国内光电子产业和科研机构资源，注重关键光电器件的自主研发。在产品 系统功能受到器件限制时，公司依旧能够在垂直方向上，通过底层技术实现性能突破。这一模 式也带 动了国内光电子器件领域在医疗方向的技术进步，体现了新质生产力对医疗设备企业的直接推动作用。 此次融资使得图湃医疗 在资本运作和研发、商业化发展上迈出了重要一步 ，更标志在眼科 ...

将向科创板眼科医疗设备"第一股"发起冲击。 本文为IPO早知道原创 作者｜Stone Jin 微信公众号｜ipozaozhidao 据IPO早知道消息，图湃医疗日前完成由社保基金中关村自主创新专项基金(由君联资本担任管理 人)、北京机器人产业投资基金、启明创投共同投资的总规模达5亿元人民币级别E轮融资。 这是继2024年6月完成D轮融资后，图湃医疗一年内再受顶级投资机构青睐。 ， 也是 国内 眼科医 疗设备领域历史上已公开一级市场投融资事件中单笔金额最高的融资 ，所融资金将持续用于图湃医 疗丰富产品矩阵及加强全球范围的市场布局等。 在完成本次E轮融资后，图湃医疗将向科创板眼科医疗设备"第一股"发起冲击。 图湃医疗始于清华大学电子工程系的科技成果转化。公司创始人、清华大学霍力教授2008年在约翰 霍普金斯大学做博士后期间就开始从事扫频OCT研究，师从Xingde Li教授，后者是OCT发明人 James G. Fujimoto教授的学生。在国家自然科学基金等多个科研项目的支持下，霍力教授带领团 队实现了一系列关键底层技术的突破和自主化。 图湃医疗成立后，眼科OCT在北京清华工业开发研究院医工转化体系中，迅速完成 ...